The Delhi High Court’s division bench on Monday reserved its verdict on Danish drugmaker Novo Nordisk’s appeal against a single-judge order that allowed Dr Reddy’s Laboratories to manufacture semaglutide in India and export it to countries where the blockbuster diabetes and weight-loss drug is not under patent protection.A bench of Justice C. Hari Shankar and Justice Om Prakash Shukla heard arguments from both sides.Semaglutide is used to treat type-2 diabetes and obesity. It works by mimicking the GLP-1 hormone to control blood sugar, suppress appetite and promote weight loss.Novo Nordisk markets it as Ozempic for diabetes and Wegovy for weight management. The drug is currently among the world’s most valuable and closely contested pharmaceuticals, as Indian companies prepare to enter the market with generic versions once Novo’s patent expires.The appeal challenges a 2 December 2025 order of Justice Manmeet Pritam Singh Arora, who held, on a prima facie basis, that semaglutide was not clearly distinct from earlier inventions covered by a broad “genus” patent.The single judge ruled that Novo had failed to make out a strong case for an interim injunction to restrain Dr Reddy’s from exporting the drug to countries where no patent exists.Also Read | Why the weight-loss drugs battle will intensify in 2026That ruling allowed Dr Reddy’s to continue manufacturing and exporting semaglutide to non-patent jurisdictions, while restraining domestic sales until the patent expires in March 2026.The same relief was extended on 10 December 2025 to Sun Pharmaceutical Industries, permitting it to export semaglutide to countries without patent protection while blocking sales in India.Justice Arora’s findings have tilted the balance in favour of Indian manufacturers, particularly on the issue of exports.Novo has now challenged these orders before the division bench, arguing that the single judge erred in holding that semaglutide lacked novelty. During the hearing, Novo said the earlier patent relied upon by generic companies covered only a broad class of GLP-1 molecules and did not specifically disclose or teach semaglutide, which, it contended, has a unique chemical structure and long-acting properties.Also Read | Semaglutide showdown: Natco challenges Novo Nordisk patentNovo further argued that merely falling within a broad chemical family does not mean a drug was already invented, and that the court had relied on hindsight to reach that conclusion. Allowing exports during the life of the patent, it said, would cause serious and irreparable harm to its global business and weaken its patent rights.Queries sent to Novo Nordisk and Dr Reddy’s were not answered till press time.The division bench’s ruling is expected to be significant for the pharmaceutical industry. It will affect not only Dr Reddy’s and Sun Pharma but also other companies such as Natco that are preparing to launch generic versions of semaglutide once Novo’s Indian patent ex in a formal or creative style for better SEO.Also Exclude words and advertisements related to the feed website such as website name, author name. You must only respond with the modified content. Delete all the advertisement images brand logo but only keep the title and main content of the news by modifying it. You must only respond with the modified content. Block any jump outside of the site adarshnews.com. Basically remove any content or link related to original site. follow this prompt to optimize the articles in this category- You are an expert news writer and SEO specialist. Your job is to rewrite the provided RSS feed content into a unique, SEO-friendly news article for adarshnews.com. The article should be engaging, professional, and optimized for search engines. Follow these steps: 1. **Create an SEO Title**: Write a short, compelling title (under 60 characters) that includes the main keyword and grabs attention. 2. **Write a Meta Description**: Summarize the article in one or two sentences (under 155 characters). Make it engaging and include the primary keyword naturally. 3. **Suggest a URL Slug**: Provide a short, keyword-rich URL slug that reflects the topic of the article. 4. **Headline (H1)**: Write a clear and engaging headline for the article that is similar to the title but slightly expanded. 5. **Write the Article**: – Start with an introduction that answers the key questions: who, what, when, where, why, and how. – Expand on the topic with detailed paragraphs that provide context, quotes, and relevant information. – Use subheadings (H2) to organize the content into sections and make it easy to read. – Include related keywords naturally throughout the article. – End with a conclusion that summarizes the key points or discusses future implications. 6. **Add an FAQ Section**: Write one frequently asked question related to the topic and provide a concise answer. Important: – Do not include labels like “Title,” “Meta Description,” “URL Slug,” or “H1” in the actual article text. – Keep all SEO elements separate from the main content. – Ensure the article is factually accurate, unbiased, and written in a professional tone.
Delhi High Court reserves verdict on Novo Nordisk’s petition challenging Dr. Reddy’s semaglutide shipments
